IMNM vs. ABVX, ETNB, SPRY, OPK, CNTA, PLRX, LQDA, ZNTL, OCUL, and ARQT Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include ABIVAX Société Anonyme (ABVX), 89bio (ETNB), ARS Pharmaceuticals (SPRY), OPKO Health (OPK), Centessa Pharmaceuticals (CNTA), Pliant Therapeutics (PLRX), Liquidia (LQDA), Zentalis Pharmaceuticals (ZNTL), Ocular Therapeutix (OCUL), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical preparations" industry.
ABIVAX Société Anonyme (NASDAQ:ABVX ) and Immunome (NASDAQ:IMNM ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.
Does the MarketBeat Community favor ABVX or IMNM?
Immunome received 20 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. Likewise, 68.57% of users gave Immunome an outperform vote while only 66.67% of users gave ABIVAX Société Anonyme an outperform vote.
Which has better valuation & earnings, ABVX or IMNM?
ABIVAX Société Anonyme has higher earnings, but lower revenue than Immunome.
Is ABVX or IMNM more profitable?
ABIVAX Société Anonyme has a net margin of 0.00% compared to ABIVAX Société Anonyme's net margin of -1,829.44%. Immunome's return on equity of 0.00% beat ABIVAX Société Anonyme's return on equity.
Do institutionals & insiders hold more shares of ABVX or IMNM?
47.9% of ABIVAX Société Anonyme shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 20.0% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Do analysts prefer ABVX or IMNM?
ABIVAX Société Anonyme presently has a consensus price target of $32.00, suggesting a potential upside of 134.60%. Immunome has a consensus price target of $30.50, suggesting a potential upside of 120.54%. Given Immunome's higher probable upside, equities research analysts plainly believe ABIVAX Société Anonyme is more favorable than Immunome.
Does the media favor ABVX or IMNM?
In the previous week, Immunome had 28 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 28 mentions for Immunome and 0 mentions for ABIVAX Société Anonyme. ABIVAX Société Anonyme's average media sentiment score of 0.38 beat Immunome's score of 0.00 indicating that Immunome is being referred to more favorably in the news media.
Summary Immunome beats ABIVAX Société Anonyme on 8 of the 13 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Immunome Competitors List
Related Companies and Tools